Inflammatory muscle disease: Clinical presentation and assessment of patients

被引：12

作者：

Alexanderson H. ^{[1
]}

Lundberg I.E. ^{[1
]}

机构：

[1] Rheumatology Unit, Karolinska University Hospital

来源：

Current Rheumatology Reports | 2007年 / 9卷 / 4期

关键词：

Myositis; Myositis Patient;

D O I：

10.1007/s11926-007-0044-8

中图分类号：

学科分类号：

摘要：

Muscle weakness and muscle fatigue are the most common manifestations in patients with idiopathic inflammatory myopathies (ie, myositis), but other organs are frequently involved such as skin, lungs, joints, and the heart. These could occur before, simultaneously with, or after the onset of muscle symptoms. One tool to structure outcome measure is the International Classification of Functioning, Disability, and Health. Measures of "disability" can be divided into impairment and activity limitation/participation restriction. Most of the available outcome measures for myositis could be classified as measures of impairment, such as muscle strength, serum levels of muscle enzymes, and pulmonary function tests. Measures of activity limitation/participation restriction are also important, such as the myositis activities profile, the visual analog scale to assess impact on general well-being, and the generic short form-36 to capture impact on health-related quality of life. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：273 / 279

页数：6

共 42 条

[1]

Arahata K., Engel A.G., Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells, Ann Neurol, 16, pp. 193-208, (1984)

[2]

Dalakas M.C., Polymyositis, dermatomyositis and inclusion-body myositis, N Engl J Med, 325, pp. 1487-1498, (1991)

[3]

Miller F.W., Rider L.G., Chung Y.L., Et al., Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheumatology (Oxford), 40, pp. 1262-1273, (2001)

[4]

The international classification of functioning, disability and health, (2001)

[5]

IMACS website

[6]

Alexanderson H., Dastmalchi M., Lundberg I.E., Patients with chronic inflammatory myopathies have reduced muscle endurance rather than reduced muscle strength, Arthritis Rheum, 54, SUPPL., (2006)

[7]

Suda T., Fujisawa T., Enomoto N., Et al., Interstitial lung disease associated with amyopathic dermatomyositis, Eur Respir J, 28, pp. 1005-1012, (2006)

[8]

Finsterer J., Stollberger C., Avanzini M., Et al., Restrictive cardiomyopathy in dermatomyositis, Scand J Rheumatol, 35, pp. 229-232, (2006)

[9]

Ohata S., Shimada T., Shimizu H., Et al., Myocarditis associated with polymyositis diagnosed by gadolinium-DTPA enhanced magnetic resonance imaging, J Rheumatol, 29, pp. 861-862, (2002)

[10]

Allanore Y., Vignaux O., Arnaud L., Et al., Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging, Ann Rheum Dis, 65, pp. 249-252, (2006)

← 1 2 3 4 5 →